The specter of generic challenges has consistently loomed over copyright’s iconic drug, Sildenafil, raising questions about the future of similar drug stakes. While first periods saw impressive profits, the exclusivity lapse has allowed the way for cheaper copies, likely lowering profitability and presenting a significant hazard for shareholders